These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23838402)

  • 1. [Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine].
    Boot J; Rump BO; Boucher CA; Op de Coul EL; van Agtmael MA; van de Vijver DA; Burger DM; Fanoy EB
    Ned Tijdschr Geneeskd; 2013; 157(27):A6063. PubMed ID: 23838402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pre-exposure prophylaxis for HIV transmission? No, unless].
    Boeke AJ; Heijnen AM
    Ned Tijdschr Geneeskd; 2013; 157(27):A6359. PubMed ID: 23838404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
    Kibengo FM; Ruzagira E; Katende D; Bwanika AN; Bahemuka U; Haberer JE; Bangsberg DR; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Kamali A; Priddy FH
    PLoS One; 2013; 8(9):e74314. PubMed ID: 24086333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
    Okwundu CI; Uthman OA; Okoromah CA
    Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD007189. PubMed ID: 22786505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
    Plosker GL
    Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
    Li J; Dufrene SL; Okulicz JF
    Ann Pharmacother; 2014 Apr; 48(4):507-18. PubMed ID: 24473492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.
    Marcus JL; Glidden DV; Mayer KH; Liu AY; Buchbinder SP; Amico KR; McMahan V; Kallas EG; Montoya-Herrera O; Pilotto J; Grant RM
    PLoS One; 2013; 8(12):e81997. PubMed ID: 24367497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
    de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
    Donnell D; Hughes JP; Wang L; Chen YQ; Fleming TR
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study).
    King HL; Keller SB; Giancola MA; Rodriguez DA; Chau JJ; Young JA; Little SJ; Smith DM
    AIDS Behav; 2014 Sep; 18(9):1722-5. PubMed ID: 25017425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.
    Murnane PM; Celum C; Mugo N; Campbell JD; Donnell D; Bukusi E; Mujugira A; Tappero J; Kahle EM; Thomas KK; Baeten JM;
    AIDS; 2013 Aug; 27(13):2155-60. PubMed ID: 24384592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-exposure prophylaxis (PrEP) in HIV-uninfected individuals with high-risk behaviour.
    Nadery S; Geerlings SE
    Neth J Med; 2013; 71(6):295-9. PubMed ID: 23956310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
    Corneli AL; Deese J; Wang M; Taylor D; Ahmed K; Agot K; Lombaard J; Manongi R; Kapiga S; Kashuba A; Van Damme L;
    J Acquir Immune Defic Syndr; 2014 Jul; 66(3):324-31. PubMed ID: 25157647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men.
    Were EO; Heffron R; Mugo NR; Celum C; Mujugira A; Bukusi EA; Baeten JM;
    AIDS; 2014 Aug; 28(13):1977-82. PubMed ID: 25259704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men.
    Dolling D; Phillips AN; Delpech V; Pillay D; Cane PA; Crook AM; Shepherd J; Fearnhill E; Hill T; Dunn D; ;
    HIV Med; 2012 May; 13(5):309-14. PubMed ID: 22151684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
    Liegler T; Abdel-Mohsen M; Bentley LG; Atchison R; Schmidt T; Javier J; Mehrotra M; Eden C; Glidden DV; McMahan V; Anderson PL; Li P; Wong JK; Buchbinder S; Guanira JV; Grant RM;
    J Infect Dis; 2014 Oct; 210(8):1217-27. PubMed ID: 24740633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian/human immunodeficiency virus containing the K65R mutation in macaques.
    Cong ME; Mitchell J; Sweeney E; Bachman S; Hanson DL; Heneine W; García-Lerma JG
    J Infect Dis; 2013 Aug; 208(3):463-7. PubMed ID: 23633402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.